Current evidence on the role of lipid lowering drugs in the treatment of psoriasis

Wang, Jiao; Zhang, Shuo; Xing, Meng; Hong, Seokgyeong; Liu, Liu; Ding, Xiaojie; Sun, Xiaoying; Luo, Ying; Wang, Chunxiao; Zhang, Miao; Li, Bin; Li, Xin

doi:10.3389/fmed.2022.900916

Cited by 11 publications

(9 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concurrent finding of upregulated LDL receptor seems counterintuitive because PCSK9 degrades the LDL receptor, which in turn would increase plasma LDL levels. A possible explanation could be that the used Olink antibodies bind to fragments of degraded LDL receptor molecules or that the concentration of LDL receptor molecules is increased due to other factors such as increased LDL – a common finding in patients with psoriasis [60].…”

Section: Discussionmentioning

confidence: 99%

Proteins in the Skin and Blood in Patients with Psoriasis: A Systematic Review of Proteomic Studies

Kromann,

Olsson,

Zhang

et al. 2023

Dermatology

View full text Add to dashboard Cite

Background: Proteins play a central role in psoriasis as they are involved in the structural phenotypic changes and inflammation that characterize the disease. This systematic review aimed to assess which proteins have been consistently reported as upregulated or downregulated in the skin and blood from patients with psoriasis. Methods: We included proteomic studies reporting differentially expressed proteins (DEPs) in at least one of four predefined comparisons using a standardized procedure to extract and align data. Network analysis of functional protein associations was made with StringApp in Cytoscape. A protocol for this review was registered in the PROSPERO database (ref:CRD42022363226). Results: We identified and assessed 772 studies published between December 2, 1996, and April 28, 2023, among which 30 studies met the inclusion and data availability criteria for analysis that together reported a sum of 5,314 DEPs. The majority of consistently reported upregulated and downregulated proteins were found in lesional versus non-lesional skin (n = 313), followed by lesional versus healthy skin (n = 185), blood from patients with psoriasis versus blood from healthy individuals (n = 140), and non-lesional versus healthy skin (n = 1). Network analysis of upregulated proteins revealed different functional clusters with interleukin (IL)-6, IL-8, IL-17A, C-C motif chemokine (CCL) 20, signal transducer and activator of transcription (STAT) 3, and interferon (IFN)-γ along with less well-studied proteins playing central roles. Some of the reported changes are associated with anti-inflammatory effects. Additionally, the proteomic dysregulation also included antimicrobial peptides, alarmins, angiogenic factors, and proteins related to protein synthesis. Conclusion: Our findings generally support current understandings of the pathological mechanisms in psoriasis. Importantly, some consistent findings have not been discussed before and deserve attention in future research.

show abstract

Section: Discussionmentioning

confidence: 99%

Proteins in the Skin and Blood in Patients with Psoriasis: A Systematic Review of Proteomic Studies

Kromann,

Olsson,

Zhang

et al. 2023

Dermatology

View full text Add to dashboard Cite

show abstract

“…Other studies have found that statins may worsen psoriasis lesions ( 67 , 68 ). A meta-analysis of randomized clinical studies in 2019 and a systematic evaluation in 2022 revealed that oral and topical statins could significantly improve psoriatic lesions and lower the PASI score, especially simvastatin ( 69 , 70 ).…”

Section: Cholesterol Metabolism and Psoriatic Inflammationmentioning

confidence: 99%

Crosstalk between cholesterol metabolism and psoriatic inflammation

et al. 2023

View full text Add to dashboard Cite

Psoriasis is a chronic autoinflammatory skin disease associated with multiple comorbidities, with a prevalence ranging from 2 to 3% in the general population. Decades of preclinical and clinical studies have revealed that alterations in cholesterol and lipid metabolism are strongly associated with psoriasis. Cytokines (tumor necrosis factor-α (TNF-α), interleukin (IL)-17), which are important in the pathogenesis of psoriasis, have been shown to affect cholesterol and lipid metabolism. Cholesterol metabolites and metabolic enzymes, on the other hand, influence not only the biofunction of keratinocytes (a primary type of cell in the epidermis) in psoriasis, but also the immune response and inflammation. However, the relationship between cholesterol metabolism and psoriasis has not been thoroughly reviewed. This review mainly focuses on cholesterol metabolism disturbances in psoriasis and their crosstalk with psoriatic inflammation.

show abstract

“…CCR6 was identified as a specific receptor for the CC motif chemokine ligand 20 (CCL20) in 1997 [ 6 ]. It is reportedly associated with various diseases, such as cancer [ 7 , 8 , 9 ], autoimmune diseases [ 10 , 11 , 12 , 13 ], psoriasis [ 14 , 15 , 16 , 17 ], and inflammatory bowel disease (IBD) [ 18 , 19 , 20 , 21 , 22 ]. The expression of CCR6 is found in B cells or T cells [ 23 ], such as effector memory T cells [ 24 ], immature dendritic cells [ 25 ], Th17 cells [ 26 ], and regulatory T (Treg) cells [ 27 ], and thus affects the activity and directionality of immune cells [ 23 , 24 , 26 ].…”

Section: Introductionmentioning

confidence: 99%

Identification of the Binding Epitope of an Anti-Mouse CCR6 Monoclonal Antibody (C6Mab-13) Using 1× Alanine Scanning

et al. 2023

View full text Add to dashboard Cite

CC chemokine receptor 6 (CCR6) is one of the members of the G-protein-coupled receptor (GPCR) family that is upregulated in many immune-related cells, such as B lymphocytes, effector and memory T cells, regulatory T cells, and immature dendritic cells. The coordination between CCR6 and its ligand CC motif chemokine ligand 20 (CCL20) is deeply involved in the pathogenesis of various diseases, such as cancer, psoriasis, and autoimmune diseases. Thus, CCR6 is an attractive target for therapy and is being investigated as a diagnostic marker for various diseases. In a previous study, we developed an anti-mouse CCR6 (mCCR6) monoclonal antibody (mAb), C6Mab-13 (rat IgG1, kappa), that was applicable for flow cytometry by immunizing a rat with the N-terminal peptide of mCCR6. In this study, we investigated the binding epitope of C6Mab-13 using an enzyme-linked immunosorbent assay (ELISA) and the surface plasmon resonance (SPR) method, which were conducted with respect to the synthesized point-mutated-peptides within the 1–20 amino acid region of mCCR6. In the ELISA results, C6Mab-13 lost its ability to react to the alanine-substituted peptide of mCCR6 at Asp11, thereby identifying Asp11 as the epitope of C6Mab-13. In our SPR analysis, the dissociation constants (KD) could not be calculated for the G9A and D11A mutants due to the lack of binding. The SPR analysis demonstrated that the C6Mab-13 epitope comprises Gly9 and Asp11. Taken together, the key binding epitope of C6Mab-13 was determined to be located around Asp11 on mCCR6. Based on the epitope information, C6Mab-13 could be useful for further functional analysis of mCCR6 in future studies.

show abstract

Current evidence on the role of lipid lowering drugs in the treatment of psoriasis

Cited by 11 publications

References 59 publications

Proteins in the Skin and Blood in Patients with Psoriasis: A Systematic Review of Proteomic Studies

Proteins in the Skin and Blood in Patients with Psoriasis: A Systematic Review of Proteomic Studies

Crosstalk between cholesterol metabolism and psoriatic inflammation

Identification of the Binding Epitope of an Anti-Mouse CCR6 Monoclonal Antibody (C6Mab-13) Using 1× Alanine Scanning

Contact Info

Product

Resources

About